SYRE
Spyre Therapeutics, Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Apr 13 ▲ Spyre Therapeutics announced positive 12-week induction data from Pa…
- Jun 15 ▲ Spyre Therapeutics announced positive 12-week induction topline data…
- Jun 24 ▼ Two directors at Spyre Therapeutics executed massive open-market sal…
- Jun 27 ▼ A massive insider selling cluster at Spyre Therapeutics (SYRE) saw $…
- Jun 30 ▲ 6 funds open new positions (13F)
- Aug 3 to Aug 7 ▼ 2 days of insider sells: $4.6M by 3 insiders, avg $100.08
- Sep 1 to Sep 2 ▼ 2 days of insider sells: $6.1M by 3 insiders, avg $87.86
- Sep 30 to Oct 1 ▼ 2 days of insider sells: $6.3M by 3 insiders, avg $91.04
- Oct 5 Offering: Spyre Therapeutics Announces Proposed Public Offering of i…
- Oct 6 Offering: Spyre Therapeutics Announces Pricing of $350.0 Million Pub…
- Oct 6 ▼ Spyre Therapeutics priced a $350M underwritten public offering of 4,…
- Oct 12 UBS initiates
Signal stack
Where each data set points today.
- InsidersBEARISH
4 insiders sold $16.9M.
- InstitutionsBULLISH
Q2 2026: 49 added (6 new), 12 trimmed or exited. Largest new: Adage Capital Partners Gp, L.L.C $152.9M, Holocene Advisors $90.1M.
- AnalystsBULLISH
21 of 23 rate it Buy or better. Every target is above the price.
- EstimatesFALLING
Current-quarter EPS estimate −$0.846 → −$0.998 over 90 days. 4 up, 7 down in 30 days.
- Short sellersSTEADY
Short interest −7.1% to 11.62M shares. 12.7 days to cover, ≈12.2% of shares.
- TrendUPTREND
8% above its 50-day average.
Who's buying
13F· Q2 2026| Fund | Move | Value |
|---|---|---|
| PRICE T ROWE ASSOCIATES INC /MD/ | ADD | $262.9M |
| GEODE CAPITAL MANAGEMENT, LLC | ADD | $239.3M |
| VANGUARD PORTFOLIO MANAGEMENT LLC | DOUBLED | $206.9M |
| Capital World Investors | DOUBLED | $205.6M |
| BANK OF AMERICA CORP /DE/ | ADD | $157.8M |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | NEW | $152.9M |
| GOLDMAN SACHS GROUP INC | DOUBLED | $131.2M |
| Holocene Advisors, LP | NEW | $90.1M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
23 analystsPrice is below the lowest target. Median implies +24%.Targets as of Nov 16, 2026.
| Date | Firm | Rating |
|---|---|---|
| Nov 4, 2026 | Guggenheim MAINTAIN | Buy |
| Nov 4, 2026 | Wedbush MAINTAIN | Outperform |
| Oct 19, 2026 | BTIG REITERATE | Buy |
| Oct 12, 2026 | UBS INITIATE | Buy |
| Oct 1, 2026 | JP Morgan INITIATE | Overweight |
| Oct 1, 2026 | BTIG REITERATE | Buy |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Burrows Scott L Chief Financial Officer Oct 1, 2026 | EXERCISE | $108.8K |
Burrows Scott L Chief Financial Officer Oct 1, 2026 | SELL | $53.4K |
Burrows Scott L Chief Financial Officer Oct 1, 2026 | SELL | $135.4K |
Burrows Scott L Chief Financial Officer Oct 1, 2026 | SELL | $193.0K |
Burrows Scott L Chief Financial Officer Oct 1, 2026 | SELL | $285.4K |
Burrows Scott L Chief Financial Officer Oct 1, 2026 | SELL | $21.4K |
King-Jones Heidy See Remarks Oct 1, 2026 | SELL | $35.7K |
King-Jones Heidy See Remarks Oct 1, 2026 | SELL | $1.5M |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$1.00 | -$1.91–-$0.50 | -16.4% | $0.00 |
| Next Q | -$0.92 | -$1.10–-$0.67 | -10.3% | $0.00 |
| Current FY | -$3.04 | -$3.95–-$2.52 | -6.9% | $0.00 |
| Next FY | -$3.69 | -$4.55–-$2.36 | -4.8% | $0.00 |
Washington
Short side
FINRA· Oct 30, 2026SecBot reports
30 filings · 6 press releases · 6 bullish · 11 bearish · 1 mixed · 12 neutral- NEUTRAL 8-KNov 3, 2026
Spyre Therapeutics reported Q3 2026 results with a net loss of $96.1M, wider than the $11.2M loss…
The mixed clinical results (IBD monotherapies positive, rheumatic disease programs discontinued) combined with the recent $350M offering create a binary event profile. Key catalysts are the SKYLINE…
- BEARISH PRESS-RELEASENov 3, 2026
Spyre Therapeutics reported Q3 2026 net loss of $96.1M ($0.94 per common share), wider than the…
The EPS miss and widening loss are tempered by a strong cash runway and positive pipeline data. Watch for SKYLINE Part B topline results in Q3 2027 and initiation of pivotal HS studies in 2027 as…
- BULLISH INST-CLUSTEROct 12, 2026
A large institutional cluster in Spyre Therapeutics (SYRE) for Q2 2026 shows 49 buyers…
The Q2 institutional accumulation is a strong bullish signal, but the $350M offering at a discount to market introduces near-term dilution and potential selling pressure. Monitor whether the…
- NEUTRAL SC 13D/AOct 9, 2026
Fairmount Funds Management LLC filed Amendment No. 8 to its Schedule 13D on Spyre Therapeutics…
Fairmount's lock-up prevents any selling by the activist for 60 days post-offering (through early December 2026). Monitor for any amendment after the lock-up expires that could signal a change in…
All SYRE filing & press-release reports (36)
- 8-K reportNov 3, 2026
- PRESS-RELEASE reportNov 3, 2026
- INST-CLUSTER reportOct 12, 2026
- SC 13D/A reportOct 9, 2026
- 8-K reportOct 7, 2026
- 424B5 reportOct 6, 2026
- PRESS-RELEASE reportOct 5, 2026
- 424B5 reportOct 5, 2026
- PRESS-RELEASE reportOct 5, 2026
- CLUSTER reportOct 2, 2026
- CLUSTER reportSep 3, 2026
- CLUSTER reportAug 10, 2026
- CLUSTER reportAug 5, 2026
- S-3ASR reportJun 26, 2026
- CLUSTER reportJul 2, 2026
- CLUSTER reportJun 26, 2026
- CLUSTER reportJun 23, 2026
- 8-K reportJun 15, 2026
- INST-CLUSTER reportJun 12, 2026
- INST-CLUSTER reportJun 11, 2026
- CLUSTER reportJun 3, 2026
- 8-K reportJun 1, 2026
- 8-K reportMay 29, 2026
- CLUSTER reportMay 1, 2026
- 8-K reportMay 5, 2026
- CLUSTER reportMay 1, 2026
- PRESS-RELEASE reportApr 14, 2026
- 424B5 reportApr 13, 2026
- PRESS-RELEASE reportApr 13, 2026
- 8-K reportApr 13, 2026
- 8-K reportApr 13, 2026
- PRESS-RELEASE reportApr 13, 2026
- DEFA14A reportApr 10, 2026
- CLUSTER reportApr 1, 2026
- PRESS-RELEASE reportApr 3, 2026
- EFFECT reportMar 2, 2026